Enrollment is complete in two Phase 2 clinical trials testing Ausperbio’s AHB-137 in people with chronic hepatitis B, the company said. That “positions us well as we move into the pivotal Phase III study of AHB-137, which was recently approved in China,” said Chris Yang, PhD, co-founder and chief scientific officer of Ausperbio, said in […] The post Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment appeared first on Liver Disease News.
